 Pyrazinamide
"Pyrazinamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazine that is used therapeutically as an antitubercular agent.
| Descriptor ID |
D011718
|
| MeSH Number(s) |
D03.383.679.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazinamide".
Below are MeSH descriptors whose meaning is more specific than "Pyrazinamide".
This graph shows the total number of publications written about "Pyrazinamide" by people in UAMS Profiles by year, and whether "Pyrazinamide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2009 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrazinamide" by people in Profiles over the past ten years.
-
Ramirez-Busby SM, Rodwell TC, Fink L, Catanzaro D, Jackson RL, Pettigrove M, Catanzaro A, Valafar F. A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis. Sci Rep. 2017 06 19; 7(1):3790.
-
Demers AM, Venter A, Friedrich SO, Rojas-Ponce G, Mapamba D, Jugheli L, Sasamalo M, Almeida D, Dorasamy A, Jentsch U, Gibson M, Everitt D, Eisenach KD, Diacon AH. Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System. J Clin Microbiol. 2016 05; 54(5):1276-81.
-
Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015 May 02; 385(9979):1738-1747.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|